P583: PATIENTS AT HIGH RISK OF RELAPSE POST-TRANSPLANT: A PHASE 1 STUDY DESIGN WITH A NOVEL TREATMENT STRATEGY USING THE ESTIMAND FRAMEWORK

• R. Zeiser,
• C. Schmid,
• G. Al-Atrash,
• Y. Xu,
• H.-J. Weber,
• L. Eldjerou,
• S. Weber,
• L. Widmer,
• C. Craddock

Affiliations

R. Zeiser

1 Department of Medicine I, Medical Center, University Freiburg, Freiburg

C. Schmid

2 Department of Hematology and Oncology, Augsburg University Hospital and Medical Faculty, Augsburg, Germany

G. Al-Atrash

3 Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston

Y. Xu

4 Oncology Analytics, Novartis Pharmaceutical Corporation, East Hanover, United States of America

H.-J. Weber

5 Oncology Analytics, Novartis Pharma AG, Basel, Switzerland

L. Eldjerou

6 Clinical Development, Novartis Pharmaceuticals Corporation, East Hanover, United States of America

S. Weber

7 Advanced Exploratory Analytics, Novartis Pharma AG, Basel, Switzerland

L. Widmer

7 Advanced Exploratory Analytics, Novartis Pharma AG, Basel, Switzerland

C. Craddock

8 Centre for Clinical Haematology, University Hospitals Birmingham NHS Foundation Trust, Birmingham, United Kingdom